What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “AV078 is a selective inhibitor of mammalian target of rapamycin complex 1 (mTORC1) administered orally once daily. Dosing may be adjusted based on measured drug concentrations to achieve target exposure levels.”In the company’s words, NCT07680322 on ClinicalTrials.gov
- Tested for
- Tuberous Sclerosis Complex, Epilepsy
- Main trialPhase 2
- “This Phase 2, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, and efficacy of oral AV078 in participants with refractory epilepsy due to tuberous sclerosis complex (TSC). Approximately 42 participants will be randomized in a 5:1 ratio to receive AV078 or placebo. The study will include a Screening Period collecting 4 weeks of pre-treatment Baseline data on seizure frequency, and progress to a 12-week Treatment Period, followed by an in person final follow-up visit approximately 2 weeks after the last dose.”In the company’s words, NCT07680322 on ClinicalTrials.gov
Other drugs for Tuberous Sclerosis Complex
- EverolimusNovartis · Phase 3
- YCJ-01 Full Spectrum cannbis ExtractOils4Cure · Phase 3
- SVG103Sovargen · Phase 1/2
- RadiprodilGRIN Therapeutics, Inc. · Phase 1/2
- Sapu003SAPU NANO (US) LLC · Phase 1
- CannabidiolJazz Pharmaceuticals · Marketed (Phase 4 trial)
Coming up1
- 1 Sep 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 1 Sep 2027 | Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1) | |
| Phase 1Completed | 8 Feb 2025 | Assessment of the Safety, Tolerability and Pharmacokinetics of AV078 in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026